PROTAC TEAD1/IAP degrader-3

PROTAC TEAD1/IAP degrader-3 是一种 TEAD1/IAP PROTAC 降解剂,可招募 cIAP1 和 XIAP E3 连接酶形成三元复合物,驱动 TEAD1 的蛋白酶体降解并触发 cIAP1 的自泛素化和蛋白酶体降解,从而抑制细胞增殖,并通过依赖 TEAD 的方式下调 CTGF 基因表达来调控 Hippo 通路活性,可用于间皮瘤的研究(粉色:TEAD1 配体 (MS-P12518);蓝色:IAP 配体 (MS-R15105);黑色:连接子)。
PROTAC TEAD1/IAP degrader-3
产品编号: MS-B80337 分子式: C47H50F4N6O6 分子量: 870.93
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PROTAC TEAD1/IAP degrader-3 是一种 TEAD1/IAP PROTAC 降解剂,可招募 cIAP1 和 XIAP E3 连接酶形成三元复合物,驱动 TEAD1 的蛋白酶体降解并触发 cIAP1 的自泛素化和蛋白酶体降解,从而抑制细胞增殖,并通过依赖 TEAD 的方式下调 CTGF 基因表达来调控 Hippo 通路活性,可用于间皮瘤的研究(粉色:TEAD1 配体 (MS-P12518);蓝色:IAP 配体 (MS-R15105);黑色:连接子)。

生物实验数据

生物活性 PROTAC TEAD1/IAP degrader-3 is a TEAD1/IAP PROTAC degrader that recruits cIAP1 and XIAP E3 ligases to form a ternary complex, driving proteasomal degradation of TEAD1 and triggering autoubiquitination and proteasomal degradation of cIAP1, thereby inhibiting cell proliferation and modulating Hippo pathway activity through TEAD-dependent downregulation of CTGF gene expression, and can be used for the study of mesothelioma (pink: TEAD1 ligand (MS-P12518); blue: IAP ligand (MS-R15105); black: linker).
IC50 & Target

cIAP1

 

TEAD1

 

体外研究
(In Vitro)

PROTAC TEAD1/IAP degrader-3 (A538) (0.0001-10 μM; 20 h) 可在 NCI-H2052 细胞中诱导 TEAD1 发生蛋白酶体依赖性降解,其 DC50 为 44 nM,最大降解率为 42%,降解依赖于 cIAP1 和 XIAP,其中 XIAP 有助于实现最大降解效力,cIAP1 则有助于提升降解剂的活性。
PROTAC TEAD1/IAP degrader-3 (0.001-10 μM; 20 h) 可在 NCI-H226 细胞中诱导 TEAD1 发生部分降解,其 DC50 为 76 nM,最大降解率为 38%。
PROTAC TEAD1/IAP degrader-3 (0.0001-30 μM; 4 h) 可在 NCI-H2052 细胞中与 cIAP1、XIAP 及 TEAD1 共同形成稳定的三元复合物。
PROTAC TEAD1/IAP degrader-3 (0.5 μM; 16 h) 可在 NCI-H2052 细胞中特异性下调蛋白质组水平的 TEAD1,而对其他 TEAD 旁系同源物无显著影响。
PROTAC TEAD1/IAP degrader-3 (1 nM-10 μM; 144 h) 可抑制 ZL55、NCI-H2052、 NCI-H226 细胞系的增殖。
PROTAC TEAD1/IAP degrader-3 (0.001-10 μM; 48 h) 在 ZL55、NCI-H2052、 NCI-H226 细胞中可通过依赖 TEAD 的方式下调 CTGF 基因表达来调控 Hippo 通路活性。

Western Blot Analysis

Cell Line: NCI-H2052 cells (stably expressing HiBiT-TEAD1; wildtype)
Concentration: 0, 0.0001,0.001, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 M
Incubation Time: 20 h
Result: Achieved 48% degradation of endogenous TEAD1 at 3 μM treatment.
Induced HiBiT-TEAD1 degradation with a Dmax of 49% and a DC50 of 293 nM.
Degraded endogenous TEAD1 with a Dmax of 42% and a DC50 of 44 nM.

Western Blot Analysis

Cell Line: NCI-H226 cells
Concentration: 0.001-10 μM
Incubation Time: 20 h
Result: Degraded endogenous TEAD1 with a Dmax of 38% and a DC50 of 76 nM.

Western Blot Analysis

Cell Line: NCI-H2052 cells
Concentration: 3 μM; 5 μM (MG132)
Incubation Time: 16 h
Result: Completely abolished TEAD1 degradation induced by 3 μM PROTAC TEAD1/IAP degrader-3 (A538), with near 100% recovery of TEAD1 levels, in the presence of MG132.

Western Blot Analysis

Cell Line: NCI-H2052 wildtype, cIAP1 KO, XIAP KO, and cIAP1/XIAP DKO cell lines
Concentration: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: 20 h
Result: Induced TEAD1 degradation in wildtype cells with a Dmax of 48% and a DC50 of 64 nM.
Reduced Dmax to 27% with a DC50 of 61 nM in XIAP KO cells.
Right-shifted DC50 to 340 nM with a Dmax of 44% in cIAP1 KO cells.
Achieved a Dmax of 28% with a DC50 of 220 nM in cIAP1/XIAP DKO cells.

Western Blot Analysis

Cell Line: NCI-H2052 cells; NCI-H226 transgenic cell lines (stably expressing HiBiT-TEAD1-4)
Concentration: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM (endogenous assay); 0.3 nM-10 μM (HiBiT assay)
Incubation Time: 20 h (endogenous assay); 18 h (HiBiT assay)
Result: Degraded TEAD4 with a Dmax of 9% and a DC50 of 510 nM in NCI-H2052 cells, compared to TEAD1 Dmax of 42% and DC50 of 44 nM.
Induced degradation of TEAD1 with a Dmax of ~40%, TEAD2 with a Dmax of <5%, TEAD3 with a Dmax of 13%, and TEAD4 with a Dmax of <5% in NCI-H226 HiBiT assays.

Cell Proliferation Assay

Cell Line: ZL55, NCI-H226, NCI-H2052 (mesothelioma cell lines); NCI-H520 (Hippo pathway-independent cell line)
Concentration: 1 nM-10 μM
Incubation Time: 144 h
Result: Inhibited proliferation in ZL55 cells with an IC50 of 925 nM and an Emax of 100%.
Inhibited proliferation in NCI-H226 cells with an IC50 of 733 nM and an Emax of 100%.
Inhibited proliferation in NCI-H2052 cells with an IC50 of 1267 nM and an Emax of 99%.
Inhibited proliferation in NCI-H520 cells with an IC50 of 443 nM and an Emax of 96%.

Real Time qPCR

Cell Line: ZL55, NCI-H226, NCI-H2052 (mesothelioma cell lines)
Concentration: 0.001-10 μM
Incubation Time: 48 h
Result: Inhibited CTGF expression in ZL55 cells with an IC50 >1000 nM.
Inhibited CTGF expression in NCI-H226 cells with an IC50 of 826 nM and an Emax of 99%.
Inhibited CTGF expression in NCI-H2052 cells with an IC50 of 875 nM and an Emax of 89%.

化学信息

分子量 870.93
分子式 C47H50F4N6O6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础